- Report
- March 2024
- 186 Pages
Global
From €3283EUR$3,374USD£2,812GBP
€3648EUR$3,749USD£3,125GBP
- Report
- February 2024
- 185 Pages
Global
From €3503EUR$3,600USD£3,001GBP
- Report
- February 2024
- 159 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Report
- April 2020
- 248 Pages
Global
From €4767EUR$4,899USD£4,083GBP
- Report
- November 2019
- 403 Pages
Global
From €4377EUR$4,499USD£3,750GBP
- Report
- October 2022
- 194 Pages
Global
From €4865EUR$5,000USD£4,168GBP
- Report
- June 2023
- 326 Pages
China
From €3892EUR$4,000USD£3,334GBP
- Report
- June 2023
- 187 Pages
China
From €1751EUR$1,800USD£1,500GBP
- Report
- October 2023
- 77 Pages
Global
From €3500EUR$3,853USD£3,103GBP
The HIV Vaccine market is a subset of the larger Vaccine market, which is focused on the development of vaccines to prevent HIV infection. HIV vaccines are designed to induce an immune response that will protect individuals from HIV infection. Vaccines are developed through a variety of approaches, including the use of live attenuated viruses, recombinant proteins, and DNA-based vaccines.
The HIV Vaccine market is highly competitive, with many companies and research institutions working to develop effective vaccines. Companies in the market include GlaxoSmithKline, Merck, Sanofi Pasteur, Johnson & Johnson, and Pfizer. Additionally, many non-profit organizations, such as the International AIDS Vaccine Initiative, are actively involved in the development of HIV vaccines. Show Less Read more
